Aridis Pharmaceuticals Inc represents values of innovation, dedication, and commitment to improving global health. The company's corporate philosophy revolves around developing targeted and effective immunotherapies for infectious diseases. Aridis Pharmaceuticals Inc is focused on pioneering the development of novel monoclonal antibodies and antiviral therapeutics to combat various pathogens. With a strong emphasis on research and development, Aridis strives to bring groundbreaking treatments to market, addressing critical unmet medical needs. By leveraging advanced technologies and strategic collaborations, Aridis Pharmaceuticals Inc aims to make a positive impact on society by providing life-saving solutions for infectious diseases.

Aridis Pharmaceuticals Inc primarily operates in the United States, focusing on the development and commercialization of innovative anti-infective therapies. With its headquarters in San Jose, California, the company leverages its proprietary technologies to address global infectious diseases. Aridis Pharmaceuticals Inc's presence extends beyond regional bounds, as it collaborates with international partners, conducts clinical trials, and explores potential expansion opportunities. Expanding its reach and impact, Aridis Pharmaceuticals Inc remains committed to delivering breakthrough treatments worldwide, combating infectious diseases and improving patient outcomes.

Aridis Pharmaceuticals Inc has achieved significant milestones in its development. The company successfully completed a Phase 1 clinical trial for its lead candidate, AR-301, a potential treatment for severe pneumonia caused by bacterial infections. Aridis also entered into a licensing agreement with Bharat Biotech to develop a vaccine for COVID-19. Furthermore, the company received a grant from the National Institutes of Health to support the development of AR-201, a potential treatment for hospital-acquired pneumonia. These achievements demonstrate Aridis Pharmaceuticals Inc's commitment to advancing innovative therapies for infectious diseases and its potential to make a significant impact in the healthcare industry.

Aridis Pharmaceuticals Inc, founded in 2003, is a biopharmaceutical company based in San Jose, California. Specializing in the discovery and development of targeted immunotherapies to treat infectious diseases, Aridis Pharmaceuticals has made significant advancements in combating severe infections. The company has a robust pipeline of novel therapies, utilizing its proprietary technologies such as Monoclonal Antibody AR-301, designed to neutralize bacterial toxins associated with severe pneumonia. Aridis Pharmaceuticals focuses on improving patient outcomes and reducing healthcare costs through the development of highly effective and safe immunotherapies. With a commitment to innovation, Aridis Pharmaceuticals is at the forefront of addressing unmet medical needs in the field of infectious diseases.

The main competitors of Aridis Pharmaceuticals Inc in the market include companies like Johnson & Johnson, Pfizer Inc, Moderna Inc, GlaxoSmithKline plc, and AstraZeneca plc.

Aridis Pharmaceuticals Inc primarily operates in the biotechnology and pharmaceutical industries.

Aridis Pharmaceuticals Inc's business model revolves around the development and commercialization of innovative anti-infective therapies. The company focuses on utilizing its proprietary technology platforms to create monoclonal antibodies that can effectively target and neutralize infectious pathogens. By harnessing the power of the immune system, Aridis Pharmaceuticals aims to provide solutions for combating a wide range of infectious diseases, including bacterial, fungal, and viral infections. Through strategic partnerships and collaborations, the company aims to accelerate the development and commercialization of its product candidates, bringing much-needed therapeutic options to patients worldwide.

Aridis Pharmaceuticals KGV ir -0,00.

Aridis Pharmaceuticals KUV ir 0,00.

AlleAktien kvalitātes vērtējums Aridis Pharmaceuticals ir 5/10.

gaidāmā Aridis Pharmaceuticals apgrozījums ir 7,75 milj. USD.

gaidāmā Aridis Pharmaceuticals peļņa ir -4,09 milj. USD.

Aridis Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of infectious diseases. The company's business model is based on several areas, including research and development, production, and distribution. Aridis focuses on the discovery and development of novel immunotherapies, particularly monoclonal antibodies and immunomodulators that specifically target the underlying pathomechanisms of infectious diseases. The company has an extensive pipeline of product candidates targeting various bacterial and viral infections. Aridis also places importance on quality and efficient processes in its production facilities. The company collaborates closely with leading pharmaceutical companies and distribution partners for international marketing and distribution. In addition to infectious diseases, Aridis aims to expand its technology and expertise in immunology to other areas such as cancer immunotherapies and autoimmune diseases. The company works with academic institutions and government agencies to enhance its research efforts and accelerate the development of novel immunotherapies. Overall, Aridis' business model is based on the development and commercialization of innovative immunotherapies for infectious diseases, with a strong focus on research and development, efficient production, and collaborations with partners.

Aridis Pharmaceuticals izmaksā dividendes 0 USD, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt Aridis Pharmaceuticals vai uzņēmums nedod dividendes.

Aridis Pharmaceuticals ISIN ir US0403341045.

Aridis Pharmaceuticals WKN ir A2N38H.

Aridis Pharmaceuticals simbols ir ARDS.

Pēdējo 12 mēnešu laikā Aridis Pharmaceuticals maksāja dividendes apmērā. Tas atbilst aptuveni dividendes ražībai. Nākamajos 12 mēnešos Aridis Pharmaceuticals plāno maksāt dividendes 0 USD apmērā.

Aridis Pharmaceuticals pašreizējā dividendu rentabilitāte ir .

Aridis Pharmaceuticals maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos .

Aridis Pharmaceuticals pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0 USD. Tas atbilst dividendes ražībai 0 %.

Aridis Pharmaceuticals tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu Aridis Pharmaceuticals apmērā 0 USD, kas tika izmaksāta 4.11.2024., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 4.11.2024..

Pēdējās dividendes izmaksa notika 4.11.2024..

Gadā 2023, Aridis Pharmaceuticals izmaksāja 0 USD dividendes.

Aridis Pharmaceuticals dividendes tiek izmaksātas USD.